Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized regorafenib exposure in metastatic colorectal cancer (therapeutic drug monitoring)
2021-000252-18Phase 2Active
- Sponsor
- CHU Rennes
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of regorafenib in metastatic colorectal adenocarcinoma (mCRC), sponsored by CHU Rennes. Primary endpoint: Overall survival. Started Feb 2021; status: active.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2021-000252-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000252-18.